^
BIOMARKER:

ALK rearrangement

i
Other names: NBLST3, CD246, Anaplastic Lymphoma Kinase, Anaplastic Lymphoma Kinase (Ki-1), CD246 Antigen, Mutant Anaplastic Lymphoma Kinase, ALK, ALK Receptor Tyrosine Kinase, Anaplastic Lymphoma Receptor Tyrosine Kinase, ALK Tyrosine Kinase Receptor
Entrez ID:
ALK rearrangement
NSCLC
crizotinib
Sensitive: A2 - Guideline
ALK rearrangement
NSCLC
alectinib
Sensitive: A2 - Guideline
ALK rearrangement
NSCLC
ALK inhibitor
Sensitive: A2 - Guideline
ALK rearrangement
NSCLC
ceritinib
Sensitive: A2 - Guideline
ALK rearrangement
NSCLC
lorlatinib
Sensitive: A2 - Guideline
ALK rearrangement
NSCLC
brigatinib
Sensitive: A2 - Guideline
ALK rearrangement
Lung Non-Squamous Non-Small Cell Cancer
ceritinib
Sensitive: B - Late Trials
ALK rearrangement
NSCLC
nivolumab
Sensitive: C2 – Inclusion Criteria
ALK rearrangement
Solid Tumor
alectinib
Sensitive: C2 – Inclusion Criteria
ALK rearrangement
NSCLC
crizotinib + bevacizumab
Sensitive: C3 – Early Trials
ALK rearrangement
LUAD
Tyrosine kinase inhibitor
Sensitive: C3 – Early Trials
ALK rearrangement
NSCLC
PD-L1 inhibitor
Resistant: C3 – Early Trials
ALK rearrangement
NSCLC
Tyrosine kinase inhibitor
Sensitive: C3 – Early Trials
ALK rearrangement
NSCLC
Immunotherapy
Sensitive: C3 – Early Trials
ALK rearrangement
NHL
ceritinib
Sensitive: C3 – Early Trials
ALK rearrangement
NSCLC
IPI-504
Sensitive: C3 – Early Trials
ALK rearrangement
NSCLC
ipilimumab
Sensitive: C3 – Early Trials
ALK rearrangement
Lung Non-Small Cell Squamous Cancer
ALK inhibitor
Sensitive: C3 – Early Trials
ALK rearrangement
RCC
crizotinib
Sensitive: C4 – Case Studies
ALK rearrangement
Sarcoma
crizotinib
Sensitive: C4 – Case Studies
ALK rearrangement
LUAD
crizotinib
Resistant: C4 – Case Studies
ALK rearrangement
LUAD
bevacizumab
Sensitive: C4 – Case Studies
ALK rearrangement
RCC
alectinib
Sensitive: C4 – Case Studies
ALK rearrangement
Lung Cancer
BMS-722782
Sensitive: D – Preclinical